1Sacco RL,Ellenberg JH,Mohr JP,et al.Infarcts of undetermined cause:the NINCDS Stroke Data Bank[J].Ann Neurol,1989,25 (4):382-390.
2Baumgartner RW,Sidler C,Mosso M,et al.Lschemic lacunar stroke in patients with and without potential mechanism other than small-artery disease[J].Stroke,2003,34 (3):653-659.
4Homma S, Di Tullio MR, Sacco RL, et al. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study. Stroke, 1994.
6Ishii S, Chang HH, Kawasaki K, et al. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity : biochemical characterization and restoration of normal intra- cellular processing by 1-deoxygalactonojirimycin [ J ]. Biochem J, 2007,406:285 - 295.
7Burlinal AP, Sims KB, Politei JM, et al. Early diagnosis of peripher- al nervous system involvement in Fabry disease and treatment of neuropathie pain:the report of an expert panel[ J. BMC Neurology, 2011,11:61.
8Motabar O, Sidransky E, Goldin E, et al. Fabry Disease - Current Treatment and New Drug Development [ J ]. Current Chemical Ge- nomics ,2010,4:50 - 56.
9Breunig F, Wanner C. Update on Fabry disease:kidney involve- ment, renal progression and enzyme replacement Therapy [ J ]. JNEPHROL,2008 ,21:32 - 37.
10Messalli G,Imbriaco M ,Avitabile G,et al. Role of cardiac MRI in e- valuating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy [ J ]. Radiol med, 2012,117(1) :19 -28.
